Overview

  • Product name

    A-1331852, BCL-XL inhibitor
  • Description

    Potent, selective BCL-XL inhibitor
  • Alternative names

    • A1331852
  • Biological description

    Potent, selective BCL-XL inhibitor (Ki < 0.01 nM). Selectively disrupts BCL-XL-BIM complexes and induces the hallmarks of apoptosis in BCL-XL-dependent Molt-4 cells.

  • Purity

    > 99%
  • CAS Number

    1430844-80-6
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    6-[8-[(2-benzothiazolylamino)carbonyl]-3,4-dihydro-2(1H)-isoquinolinyl]-3-[5-methyl-1-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylic acid
  • Molecular weight

    658.81
  • Molecular formula

    C38H38N6O3S
  • PubChem identifier

    71565985
  • Storage instructions

    Shipped at 4°C. Store at -20°C. Store under desiccating conditions.
  • Solubility overview

    Soluble in DMSO to 100 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES

    CC1=C(C=NN1CC23CC4CC(C2)CC(C4)C3)C5=C(N=C(C=C5)N6CCC7=CC=CC(=C7C6)C(=O)NC8=NC9=CC=CC=C9S8)C(=O)O
  • Source

    Synthetic

References

This product has been referenced in:

  • Lucas CM  et al. High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia. Leukemia 30:1273-81 (2016). Read more (PubMed: 26987906) »
  • Leverson JD Chemical parsing: Dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors. Mol Cell Oncol 3:e1050155 (2016). Read more (PubMed: 27308564) »
  • Leverson JD  et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 7:279ra40 (2015). Read more (PubMed: 25787766) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab218112.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up